Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer

Journal of Clinical Oncology

Volumn 26, Issue 11, 2008, Pages 1907-1908

  Punt, Cornelis J A ^a   Koopman, Miriam ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CELECOXIB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CAPECITABINE IRINOTECAN COMBINATION; CAPECITABINE-IRINOTECAN COMBINATION; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADVANCED CANCER; CANCER GROWTH; CANCER INCIDENCE; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEALTH CARE ORGANIZATION; HUMAN; LETTER; MEDICAL EDUCATION; MEDICAL INFORMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ADENOCARCINOMA; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; DRUG ADMINISTRATION; METASTASIS; NOTE; PATHOLOGY; VOMITING;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEHYDRATION; DEOXYCYTIDINE; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VOMITING;

EID: 42949114492     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.9640     Document Type: Letter

References (10)

1. Fuchs CS, Marshall J, Mitchell E, et al: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study. J Clin Oncol 25:4779-4786, 2007
2. Kohne CH, De Greve J, Hartmann JT, et al: Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol doi:10.1093/annonc/mdm544 [epub ahead of print on December 6, 2007]
3. Koopman M, Antonini NF, Douma J, et al: Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370:135-142, 2007
4. Bajetta E, Di BM, Mariani L, et al: Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 100:279-287, 2004
5. Borner MM, Bernhard J, Dietrich D, et al: A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: Efficacy, quality-of-life and toxicity. Ann Oncol 16:282-288, 2005
6. Patt YZ, Lee FC, Liebmann JE, et al: Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: Phase II trial results. J Clin Oncol 30:350-357, 2007
7. Rea DW, Nortier JW, Ten Bokkel Huinink WW, et al: A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol 16:1123-1132, 2005
8. Javle MM, Cao S, Durrani FA, et al: Celecoxib and mucosal protection: Translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. Clin Cancer Res 13:965-971, 2007
9. Haller DG, Cassidy J, Clarke S, et al: Tolerability of fluoropyrimidines appears to differ by region. J Clin Oncol 24:18s, 2006 (abstr 3514)
10. Sorbye H, Kohne CH, Sargent DJ, et al: Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: A proposal for standardization of patient characteristic reporting and stratification. Ann Oncol 18:1666-1672, 2007